bioRxivPathology
Sotrovimab retains activity against SARS-CoV-2 Omicron variant BQ.1.1 in a non-human primate model
C. Herate, R. Marlin, F. Touret, N. D. Bosquet, F. Donati, F. Relouzat, L. Junges, M. Galhaut, O. Dehan, Q. Sconosciutti, A. Nougairede, X. de Lamballerie, S. van der Werf, R. Le Grand
Abstract
The SARS-CoV2 Omicron variants have acquired new Spike mutations leading to escape from the most of the currently available monoclonal antibody treatments reducing the options for patients suffering from severe Covid-19. Recently, both in vitro and in vivo data have suggested that Sotrovimab could retain partial activity against recent omicron sub-lineage such as BA.5 variants, including BQ.1.1. Here we report full efficacy of Sotrovimab against BQ.1.1 viral replication as measure by RT-qPCR in a non-human primate challenge model.
- organism: non-human primate
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model
J.-S. Driouich, O. Bernadin, … A. Nougairede·bioRxiv·Jan 4, 2023
- Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 Omicron sub-lineages
F. Touret, E. Giraud, … X. de Lamballerie·bioRxiv·Dec 22, 2022
- In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate
F. Touret, C. Baronti, … X. de Lamballerie·bioRxiv·Jan 1, 2022
- Antibody Evasion Properties of SARS-CoV-2 Omicron Sublineages
S. Iketani, L. Liu, … D. D. Ho·bioRxiv·Feb 7, 2022
- Frequent emergence of resistance mutations following complex intra-host genomic dynamics in SARS-CoV-2 patients receiving Sotrovimab
R. P. Cabrera, F. Tejerina, … L. Perez-Lago·Antimicrobial Agents and ChemotherapyPeer-reviewed·Jul 18, 2023
- Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies
D. Planas, T. Bruel, … O. Schwartz·bioRxiv·Nov 17, 2022